Clinical Trials in Oncology

Jacob Fleming Conferences16-17 September 2010, Budapest, Hungary.
Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

Attend to explore effective patient recruitment and enrollment strategies and understand regulatory considerations surrounding clinical trials in oncology. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on conducting clinical trials in emerging markets in CEE, APAC and India.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from the pharmaceutical industry as well as from the oncology-focused institutions and organizations. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Vice President, Chief Clinical Officer, Teva, Israel
  • Global Clinical Operations Head Oncology, Johnson & Johnson, UK
  • Chief Medical Officer, Kiadis Pharma, The Netherlands
  • Group Head Clinical Project Management, Pfizer, Germany
  • Clinical Trials Consultant to MHRA, UK
  • Clinical Trial Head, Novartis, Switzerland
  • CRUK Professor of Translational Cancer Research, University of Glasgow, UK
  • Director Clinical Research Internal Medicine Early Stage Development, Merck Sharp & Dohme, The Netherlands
  • Principal Clinical Development Scientist, GlaxoSmithKline, UK
  • Executive Director, Oncology Global Development and Medical Affairs, Bristol Myers Squibb, France
  • Group Leader Global Clinical Development Unit Oncology, MerckSerono, Germany

Key topics:

  • Recruitment and enrollment in clinical trials. Expectations and reality.
  • Current regulatory situation in relation to clinical trials in the EU
  • Biomarkers as valuable decision making tools in clinical drug development
  • How are Pharma companies implementing and managing adaptive clinical trial
  • Challenges and opportunities of conducting clinical trials in Emerging Markets

Who should attend:
Vice presidents, Global heads, Heads, Directors, Senior managers, Managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/clinical-trials-in-oncology

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]